BIOCIENCIAS: Bª Y CLÍNICA DEL CÁNCER Y MEDIC. TRASLACIONAL
Escuela de doctorado
NOEMI
PUIG MORON
Investigadora desde null
Publicaciones en las que colabora con NOEMI PUIG MORON (67)
2024
-
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
Blood, Vol. 143, Núm. 7, pp. 597-603
2023
-
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031
-
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
Nature Communications, Vol. 14, Núm. 1
-
Multiple myeloma with t(11;14): impact of novel agents on outcome
Blood Cancer Journal, Vol. 13, Núm. 1
-
Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma
Cancers, Vol. 15, Núm. 5
2022
-
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161
-
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781
-
Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma
Archives of pathology & laboratory medicine, Vol. 146, Núm. 7, pp. 862-871
-
MM-198 Anti-BCMA Therapy in Multiple Myeloma: A Single-Center Experience
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S413
-
MM-202 Impact of t(11;14) in Multiple Myeloma on Response to Treatment and Survival
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S413-S414
2021
-
6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival
British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852
-
Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study
Modern Pathology, Vol. 34, Núm. 1, pp. 59-69
-
B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients
Cancers, Vol. 13, Núm. 7
-
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma
Blood, Vol. 137, Núm. 1, pp. 49-60
-
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis
Blood Cancer Journal, Vol. 11, Núm. 2
-
Monocyte subsets and serum inflammatory and bone-associated markers in monoclonal gammopathy of undetermined significance and multiple myeloma
Cancers, Vol. 13, Núm. 6, pp. 1-18
-
Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma
Cancers, Vol. 13, Núm. 19
2020
-
A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients
Journal of Molecular Diagnostics, Vol. 22, Núm. 1, pp. 60-71
-
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma
Blood, Vol. 135, Núm. 26, pp. 2375-2387
-
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma
Leukemia, Vol. 34, Núm. 11, pp. 3007-3018